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Abstract: When surgical ligation of bleeding fails, or is not possible, surgeons rely on a number 
of hemostatic aids, including thrombin. This review discusses the history, pharmacology and 
clinical application of thrombin as a surgical hemostat. The initial thrombin was bovine in 
origin, but its use has been complicated by the formation of antibodies that cross react with 
human coagulation factors. This has been associated with life threatening bleeding and in some 
circumstances anaphylaxis and death. Human thrombin, isolated from pooled plasma of donors, 
has been developed in an effort to minimize these risks, but its downside is the potential of 
transmitting blood-borne pathogens and limited availability. Recently a recombinant thrombin 
has been developed and approved for use by the FDA. It has the advantage of being minimally 
antigenic and devoid of the risk if viral transmission. Thrombin is often used in conjunction with 
other hemostatic aids, including absorbable agents (like gelfoam, collagen, and cellulose), and 
with ﬁ  brinogen in ﬁ  brin glues. The last part of this review will discuss these agents in detail, 
and review their clinical applications.
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Introduction
In any surgical procedure, hemostasis is vital to success. When surgical ligation of 
bleeding fails, or is not possible, surgeons rely on a number of hemostatic aids. One 
such hemostatic ancillary is thrombin.
Thrombin has a long history as a vehicle to affect hemostasis. Descriptions can 
be found in the European literature as early as 1892 for the use of thrombin (Brister 
et al 1994). Early on, thrombin was used by barbers and boxers, for hemostasis of 
shaving cuts and ﬁ  ght lacerations. Records citing thrombin use in surgery date back 
to the 1940s. Since then its use has grown exponentially, and now thrombin is used in 
more than 1 million patients in the United States each year at a cost of US$250 million 
(Lawson 2006). Recently there have been new developments in thrombin, namely FDA 
approval in human thrombin, and development of a recombinant thrombin.
This review will discuss the mechanism by which thrombin acts, the history of 
bovine thrombin, the development of human thrombin, methods of thrombin delivery 
in clinical applications, and ﬁ  nally the future of thrombin in regards to recombinant 
technologies.
Mechanism of thrombin
Thrombin has a number of well studied biological activities, which serve to achieve 
coagulation and hemostasis. With tissue injury and bleeding, exposed collagen and 
released tissue factor cause activation of the intrinsic and extrinsic coagulation pathways. 
Both pathways lead to activation of factor X which along with activated factor V forms 
a complex that cleaves the prothrombin protein into the active thrombin molecule. 
Thrombin production is the ﬁ  nal coagulation step required to cleave ﬁ  brinogen into ﬁ  brin Biologics:   Targets & Therapy 2008:2(4) 594
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which provides a hemostatic lattice for platelet aggregation 
and thrombus formation at the site of injury (Figure 1).
In addition to the coagulation cascade, thrombin can act 
directly on a number of cell types. At the smooth muscle cell, it 
causes vasoconstriction which aids in hemostasis. By activating 
platelets it promotes their aggregation at the site of thrombus. 
Activated thrombin also acts as a mitogen and chemoattractant 
for neutrophils, ﬁ  broblasts, and even induces the formation of 
VEGF for tissue and vascular remodeling and repair (Brister 
et al 1994; Patterson et al 2001; Lawson 2006).
Interestingly, thrombin not only promotes coagulation, but 
it can also activate the anticoagulant system through protein C. 
When there is vascular injury the procoagulant effects 
of thrombin are activated as described above. However, when 
there is no vascular disruption, thrombin will interact with 
thrombomodulin to activate protein C to improve circulation 
through an anticoagulant effect (Dahlback 2000).
Through all of these varied actions, thrombin promotes 
and modulates coagulation. For the purpose of this treatise 
we will conﬁ  ne the discussion to its pro-thrombotic role and 
how that has been harnessed to limit bleeding in a variety of 
surgical procedures.
Bovine thrombin
The initial source of thrombin was from a bovine origin 
and its effectiveness at facilitating surgical hemostasis 
resulted in it quickly becoming a popular surgical ancillary. 
With increased usage and thus patient exposure, isolated 
case reports surfaced suggesting that bovine thrombin may 
be operational in surgically related bleeding abnormalities. 
The ﬁ  rst report in the literature questioning bovine thrombin 
safety was in 1989 by Flaherty et al (1989). He identiﬁ  ed 
four patients with prior bovine thrombin exposure and unex-
plained prolonged thrombin times (greater than 300 seconds). 
Mixing studies suggested the presence of an inhibitor, and 
the thrombin test times were able to be corrected if human 
thrombin was substituted for bovine thrombin in the test 
reagents. The antibodies to bovine thrombin were isolated 
from the patients, and found to prolong the thrombin times 
if added to the plasma of normal patients.
The actual antibody generated by bovine thrombin 
exposure was further characterized by Zehnder in 1990 
(Zehnder and Leung 1990). He reported a 65-year-old 
patient who underwent a cardiac procedure complicated 
by uncontrolled and persistent postoperative bleeding. The 
patient’s factor V activity was 1% of normal and was not 
corrected by mixing with normal plasma, demonstrating the 
presence of an inhibitor against factor V. This inhibitor was 
found to be an antibody of bovine factor V that cross reacted 
with the patient’s own factor V (Figure1). The source of the 
bovine factor V was from the bovine thrombin preparation 
which contained not only thrombin, but other bovine plasma 
proteins. Similar case reports soon surfaced documenting 
coagulopathy that was associated with bovine thrombin 
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Figure 1 Diagram of coagulation cascade. Blue boxes and arrows include various hemostatic agents with their mechanism of actions. (+) these agents affect the entire 
coagulation cascade by concentration and creating of a matrix for coagulation factors at the bleeding site. Red arrows indicate the inhibition caused by bovine generated 
antibodies to thrombin, factor V, and platelet antiphospholipids.Biologics:   Targets & Therapy 2008:2(4) 595
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exposure. Additional bovine thrombin antibodies have been 
isolated, including antibodies to the bovine thrombin itself 
(Lawson 1990; Rapaport et al 1992).
In 1994, Ortel reported a case series of four patients 
with acquired factor V inhibitors from presumed repeated 
exposure to bovine thrombin preparations. The authors 
reviewed the literature and identiﬁ  ed an additional thirteen 
patients with documented bovine thrombin preparation 
induced factor V antibodies. They noted that even though 
all seventeen patients had the factor V inhibitor, each patient 
had a different clinical course ranging from asymptomatic to 
life threatening hemorrhage (Ortel et al 1994). Despite the 
accumulating data concerning factor V antibody generation, 
the commercial use of bovine thrombin continued and in 
fact increased. However, by 1996 the weight of the evidence 
resulted in the FDA attaching a Black Box drug warning label 
to all bovine thrombin containing products (Lawson 2006).
In addition to hemorrhage, case reports of thrombotic 
reactions to antibodies generated by bovine thrombin 
preparations began to surface. In a study with 88 hemodi-
alysis patients (Sands et al 2000) and another case report 
with 1 cardiac patient (Fastenau et al 1999), the authors 
demonstrated certain patients exposed to bovine thrombin 
preparations could developed antiphospholipid antibodies 
causing subsequent thrombosis. More bovine thrombin 
induced antibodies continued to be discovered, as mice 
experiments by Schoenecker et al in 2001 demonstrated 
autoantibodies similar to those found in autoimmune disor-
ders like SLE could be caused by bovine thrombin exposure 
(Schoenecker et al 2001).
To better delineate the incidence of antibody formation 
following bovine thrombin exposure, Ortel in 2001 
prospectively studied 151 patients undergoing cardiac 
surgery. The authors found more than 95% of patients 
developed a seropositive response to bovine coagulation 
proteins, and 51% manifested elevated antibody levels to 
the corresponding human coagulation proteins after bovine 
thrombin exposure. Furthermore, 15 of these 151 patients had 
previous surgeries and were positive for preoperative anti-
bodies to bovine proteins from assumed previous thrombin 
exposure. These 15 had signiﬁ  cantly more adverse effects 
(73.3%) than those without previous surgery or antibodies 
(33.8%), p = 0.0042 (Ortel et al 2001).
In 2002, another review by Streiff documented 126 
cases of factor V inhibitors found in the medical literature. 
These cases included patients with spontaneous and bovine 
thrombin induced factor V inhibitors. Interestingly a majority 
of the cases were found in the previous 10 years indicating an 
increasing incidence. Fifty-eight of the patients were bovine 
thrombin-induced only, and 33% developed some sort of 
bleeding complication (Streiff and Ness 2002).
Almost every surgical specialty has had a case study or 
series of adverse events related to the use of bovine thrombin; 
neurosurgery (Spero 1993; Banninger et al 1993; Poynton 
et al 2003), pediatric surgery (Muntean et al 1994; Israels and 
Israels 1994; Israels and Leaker 1997; Savage et al 2007), 
cardiac surgery (Banninger et al 1993; Berruyer et al 1993; 
Lawson et al 2005), ob-gyn (Adams et al 2001), vascular 
(Kajitani et al 2000; Sarfati et al 2004), and nephrology 
(Pavlovich et al 2001). Despite this evidence bovine thrombin 
continues to be widely used, and its market has grown to a 
reported US$247 million in 2007 (Timmerman 2007). The 
major reason for the continued popularity of bovine thrombin 
was the lack of an alternative thrombin preparation. However, 
human thrombin and more recently a recombinant thrombin 
are now available and pose a challenge to bovine thrombin 
in the surgical ancillary market.
Human thrombin
The adverse immunological effects associated with bovine 
thrombin have lead to the development of thrombin from 
alternative sources. Human derived thrombin is one such 
alternative. Human thrombin is isolated from pooled 
human plasma donors at US licensed collection centers. All 
donors are tested for blood-borne diseases (HIV, hepatitis, 
parvovirus B19). The plasma is then processed through a 
series of separation and ﬁ  ltration steps followed by incubation 
of the solution with calcium chloride to isolate and activate 
prothrombin to thrombin. The solution subsequently under-
goes ultraﬁ  ltration, vapor heat treatment, solvent-detergent 
treatment, sterile ﬁ  ltration, and freeze-drying.
The vapor heat and solvent-detergent treatment steps used 
in the manufacturing process have been shown to be capable 
of signiﬁ  cant viral reduction. No procedure, however, has 
been shown to be completely effective in removing viral 
infectivity from derivatives of human plasma. Therefore 
although relatively safe, there is still no assurance that 
human thrombin is completely free of blood-borne pathogens 
(Jackson 2001; Baxter 2007; Heffernan et al 2007; Omrix 
Biopharmaceuticals 2007). An additional issue is the ﬁ  nite 
availability of human derived blood products and whether 
the supply can be sufﬁ  cient for the potential demand.
In 2007, the FDA finally approved the first stand 
alone human thrombin preparation, Evithrom® (Omrix 
Biopharmaceuticals, Ltd, New York, NY, USA) (US Food 
and Drug Administration 2007). Previously, human thrombin Biologics:   Targets & Therapy 2008:2(4) 596
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was only used in FDA approved combination products, 
namely Floseal® (Baxter; Deerﬁ  eld, IL, USA), and the ﬁ  brin 
glues (to be discussed in greater detail later).
Results from an unpublished clinical trial of Evithrom® 
versus bovine thrombin can be found in the packet insert for 
Evithrom®. In a phase III, prospective, randomized, controlled, 
double-blinded study of 305 subjects at 22 centers in the US, 
subjects undergoing elective cardiovascular, neurological 
(spinal) or general surgical procedures were randomized to 
treat oozing or bleeding (of mild intensity that could not be 
controlled by other surgical techniques) with bovine thrombin 
and Surgifoam® (Johnson and Johnson Wound Management; 
Somerville, NJ, USA) or Evithrom® and Surgifoam®. Treat-
ment with Evithrom® was as successful as treatment with 
bovine thrombin in achieving the primary efﬁ  cacy endpoint: 
hemostasis within 10 minutes of product application. The 
secondary efﬁ  cacy endpoint of hemostasis within 6 and 
3 minutes of product application also was achieved. There 
was no difference in safety between the two groups.
In the Evithrom® group there were 17% serious adverse 
events as compared to 11% in the bovine thrombin group. 
Two subjects (1.3%) in the Evithrom® group experienced a 
severe adverse event: respiratory arrest and post-procedural 
hematoma in one subject and an extradural hematoma in 
the other. Three subjects in the bovine thrombin group 
experienced severe adverse events: hyperhidrosis, pyrexia, 
and post-procedural hematoma. None of the adverse events 
reported was considered causally related to Evithrom® or 
bovine thrombin administration. No deaths were reported 
during the study period (Omrix Biopharmaceuticals 2007).
Recombinant human thrombin 
(rhThrombin)
The development of a recombinant human thrombin, Reco-
throm® (Zymogenetics Inc; Seattle, Washington, USA), 
provides a manufactured source of thrombin that is devoid 
of the risks of antibody development found with bovine 
thrombin or the theoretic risks of viral transmission with 
human derived thrombin. Recombinant thrombin has the 
identical amino acid sequence as human thrombin, and is 
made from a genetically modiﬁ  ed Chinese hamster ovary 
cell line. Although hypothetically, Recothrom® is free from 
infectious agents, there is still a ﬁ  nal puriﬁ  cation process 
with solvent-detergent treatment and nano-ﬁ  ltration. This 
product was approved by the US FDA in January 2008 
(Zymogenetics 2008).
Phase 1 animal trials demonstrated rhThrombin to be safe 
in animal subjects (Heffernan et al 2007). Phase 2 trials have 
been completed comparing the safety proﬁ  le of rhThrombin 
to placebo. One hundred thirty patients undergoing AV graft, 
liver resections, peripheral artery bypass, and spinal surgery 
were randomized to either rhThrombin or placebo soaked in 
Gelfoam® (Pharmacia and Upjohn, Briggewater, NJ, US) or 
Surgifoam®. No patterns of treatment-related adverse events 
were associated with rhThrombin. Recombinant thrombin 
induced minimal antibody generation and no antibody medi-
ated reactions to coagulation proteins were documented 
(Chapman et al 2006).
A recently published phase 3 trial compared the efﬁ  -
cacy, safety, and antigenicity of rhThrombin versus bovine 
thrombin. In 401 patients undergoing liver resection, spine, 
peripheral arterial bypass, and dialysis access surgery were 
randomly assigned to either rhThrombin or bovine thrombin 
(bThrombin) for surgical hemostasis. A gelatin sponge was 
used as a carrier. Hemostasis was achieved at the time-to-
hemostasis evaluation site within 10 minutes in 95% of 
patients in each treatment group. Overall complications, 
including operative mortality, adverse events, and labora-
tory abnormalities, were similar between groups. However, 
in terms of antigenicity, 21.5% of the patients receiving 
bovine thrombin developed antibodies to the product whereas 
only 1.5% in the rhThrombin group developed antibodies to 
rhThrombin, p  0.0001.
In post hoc analysis, those that developed anti-bThrom-
bin antibodies (n = 43) had a numerically higher incidence 
of bleeding, thromboembolic events, hypersensitivity, and 
abnormal aPTT compared with those in the bThrombin group 
that did not develop antibodies (n = 157). This increase was 
not seen in those with anti-rhThrombin antibodies (n = 3) 
compared with those in the rhThrombin group that did not 
develop antibodies (n = 195) (Chapman et al 2007).
Currently in publication is the companion study for the 
vascular subgroup in the previously mentioned phase 3 trial. 
In this population, the improved antigenicity proﬁ  le was 
again noted for rhThrombin versus bThrombin, and in the 
peripheral arterial bypass subgroup the time to hemostasis 
was actually better in the rhThrombin group when compared 
to the bThrombin group (Weaver et al 2008).
Mechanisms for delivery
Thrombin is used predominantly as a topical agent for 
bleeding that cannot be controlled with suture ligation or 
electrocautery. It is particularly useful in neurosurgical 
applications near the spine, in liver surgery where there is 
raw liver surface bleeding, and in vascular surgery where 
needle holes in PTFE grafts continue to ooze.Biologics:   Targets & Therapy 2008:2(4) 597
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There are many ways thrombin is used during a surgi-
cal procedure to effect hemostasis. It can be used alone, in 
combination with an absorbable hemostatic carrier, or in a 
manufactured combination with ﬁ  brin. Given the discussion 
previously, it is important to know the source of thrombin 
(bovine, human, recombinant), and the source of any other 
additives in the manufactured preparations.
Thrombin use alone
In the past pure thrombin was only available from a bovine 
source, and manufactured as thrombin-JMI® (King Pharma-
ceuticals, Inc, Bristol, TN, US). Now there is also an FDA 
approved human thrombin (Evithrom®) and just recently, a 
recombinant thrombin (Recothrom®).
Thrombin-JMI® and Recothrom® are stored at room tem-
perature, as a powder, which is reconstituted with saline into 
solution for use. (Zymogenetics 2008, King Pharmaceuticals 
Inc 2007). Evithrom® is packaged as a solution, and stored in 
a freezer. Otherwise it can be refrigerated for up to 30 days, 
or kept at room temperature for up to 24 hours. (Omrix Bio-
pharmaceuticals 2007). All stand alone thrombin, regardless 
of origin, are applied as a solution and can be cumbersome 
for topical application unless sprayed into a mist, or used with 
another carrier (like the absorbable hemostatic agents) or in 
combination with ﬁ  brinogen to create a “glue”.
Thrombin and absorbable hemostatic 
agents
Absorbable hemostatic agents include: gelatin sponge, 
oxidized regenerated cellulose, and microﬁ  brillar collagen. 
These agents can be used alone or in combination with 
thrombin. They all are porous structures that provide a 
framework for platelet and coagulation factor activation 
(Figure 1 [+]). This implies there must be functional coagula-
tion factors present for clot to form (Wagner et al 1996).
One issue with these agents is there porous nature can cause 
expansion. In closed spaces like the spinal canal, cases have 
been reported where this expansion leads to spinal cord com-
pression injuries. (Sabel and Stummer 2004). In addition, there 
is also the possible risk of embolization if applied to open arte-
rial bleeding rather than diffuse oozing. However, these risks are 
low and the user friendly nature of the absorbable hemostatic 
agents makes them a popular surgical ancillary which are 
widely and frequently used by most surgical specialties.
Gelatin sponge
Gelatin sponges for surgical use were ﬁ  rst introduced in the 
1940s for neurosurgical procedures. The gelatin consists of 
a puriﬁ  ed pork or bovine skin. Its surface causes activation 
of the intrinsic coagulation pathway but its main effect 
is its ability to absorb approximately 45 times its weight, 
expanding to approximately 200% of its initial volume. This 
facilitates a concentration of coagulation factors at the site 
of bleeding. A number of manufactured versions exist, and 
it is available as a sheet, powder, prepackaged in a syringe, 
or even prepackaged with thrombin.
Gelfoam® (Pharmacia and Upjohn, Briggewater, NJ, US) 
comes in sheets, Surgifoam® (Johnson and Johnson Wound 
Management) is also a sheet or powder, and Surgiﬂ  o® (Johnson 
and Johnson Wound Management) is available in an applicator 
syringe that allows for the addition of any thrombin solution. 
All these products carry a theoretic risk for antigenicity given 
they are derived from non-human sources, but to date no 
adverse events have been linked to gelatin formulations.
Floseal® (Baxter; Deerﬁ  eld, IL, US) is a prepackaged 
gelatin matrix with a separate human thrombin component. This 
human thrombin is a powder that is reconstituted with a calcium 
chloride solution then mixed with the gelatin matrix in a deliv-
ery syringe. Initially, both the gelatin and thrombin were from 
bovine origin, but in 2002 Baxter replaced the bovine thrombin 
with pooled human plasma thrombin. (Baxter 2005).
Oxidized regenerated cellulose
Introduced in the 1940s, as well, oxidized regenerated 
cellulose is now marketed as Surgicel® (Johnson and Johnson 
Wound Management). This product looks like cloth, and 
in fact is basically treated cotton. Oxidation converts the 
hydroxyl groups into carboxylic acid, and this allows for 
denaturation of blood proteins initiating hemostasis. Regen-
eration implies the cotton is initially dissolved then extruded 
as a continuous ﬁ  ber which can then be manufactured into 
desired conﬁ  gurations. Surgicel Nu-Knit® is made into thick 
sheets, and Surgicel Fibrillar® is a more loosely woven 
structure arrangement. Of note Surgicel® is bacteriostatic 
and absorbs in 1–2 weeks. (Frantz et al 1944).
Microﬁ  brillar collagen
Avitene® (Bard; Cranston, RI, US) and INSTAT® (Johnson 
and Johnson Wound Management) are microﬁ  brillar collagen 
agents. Bovine collagen is processed and puriﬁ  ed into water-
insoluble acid salts that initiate platelet activation. Avitene® can 
be manufactured into small particles, sheets, and sponges.
Thrombin and ﬁ  brinogen (ﬁ  brin glue)
Fibrin glues contain thrombin and fibrinogen. When 
combined the fibrinogen is activated by thrombin and Biologics:   Targets & Therapy 2008:2(4) 598
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converted into ﬁ  brin monomers. This forms an adhesive 
glue at the tissues applied. The ﬁ  brin monomers go on to 
interact with the patient’s own factor XIII and calcium to 
convert the ﬁ  nal product into a ﬁ  brin polymer that allows 
for platelet activation and aggregation with subsequent 
hemostasis (Figure 1).
Fibrin glues come packaged with a dual chamber syringe 
that allows for the combination of the thrombin and ﬁ  brinogen 
after the plunger is depressed. Commercially available 
products include Tisseel® (Baxter; Deerﬁ  eld, IL, US) and 
Evicel® (Johnson and Johnson Wound Management). All 
components in Evicel®, formerly Crosseal®, are human 
derived (Johnson and Johnson Wound Management 2007). 
Tisseel® uses thrombin and ﬁ  brinogen derived from human 
sources, but there is an additional ﬁ  brinolysis inhibitor added 
to the ﬁ  brinogen component to prevent premature ﬁ  brinolysis 
after the ﬁ  brin glue is applied. This ﬁ  brinolysis inhibitor 
was originally extracted from bovine, but in 2007 this was 
replaced with a synthetic inhibitor, rendering Tisseel® bovine 
free (Baxter 2007).
Indications for use
All the above combination products are effective and none 
have demonstrated singular superiority with the exception of 
a few speciﬁ  c surgical settings. Currently, bovine thrombin 
is the most common thrombin used alone or in combination 
with a gelatin sponge. Manufactured combination products 
such as the ﬁ  brin glues and Floseal® contain almost exclu-
sively human thrombin. Recombinant thrombin which 
was just recently approved may replace bovine or human 
thrombin in many of these applications, but to what degree 
remains to be seen.
For any given surgical procedure, which thrombin or 
combination product is mainly dependent on surgeon prefer-
ence. In general, the stand alone thrombin spray is used to 
assist in hemostasis of large raw surface areas such as in the 
case of solid viscera injury and resection of retroperitoneal 
tumors. Gelatin/thrombin combinations are very helpful 
in achieving hemostasis in vascular and spinal procedures 
and the ﬁ  brin glues are most commonly used in reoperative 
cardiac procedures, complicated by persistent and difﬁ  cult 
to control mediastinal bleeding. The effectiveness of the 
gelatin/thrombin combination to achieve hemostasis has 
been extensively studied and found to be quite effective. The 
different ﬁ  brin glues have also been studied in numerous sur-
gical settings including liver resections (Schwartz et al 2004), 
vascular PTFE grafts (Glickman et al 2002; Taylor et al 
2003), and even inguinal hernia repairs (Canonico 2003).
Conclusions
Thrombin has had a long history in surgical hemostasis, and 
has proven to be a useful and effective ancillary for surgi-
cal hemostasis. Early bovine thrombin formulations have 
been conclusively linked to the development of antibodies 
that cross react with multiple human coagulation proteins, 
factor V being the most important. These bovine induced 
antibodies to human coagulation factors have led to numerous 
cases of life threatening bleeding and other complications. 
The recent FDA approval of human thrombin has provided 
an alternative to bovine thrombin, but has the theoretic risk 
of viral transmission. The more recent development and 
FDA approval of a recombinant protein thrombin product 
provides yet another potential alternative, with equal efﬁ  cacy 
to bovine thrombin, without the attendant risk of antigenicity 
(Chapman et al 2007).
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